Connect with us

Technology

RAAPID Brings on Healthcare Experts to Strengthen Leadership and Drive Growth

Published

on

LOUISVILLE, Ky., March 26, 2025 /PRNewswire/ — RAAPID, the industry-leading risk adjustment AI company, has announced the addition of two key executives to strengthen its leadership team as the company continues its growth trajectory. Wynda Clayton has joined as Director of Risk Adjustment Coding and Compliance, while Derek Haynes steps into the role of Director of Partner Alliances.

Clayton joins RAAPID after roles as a Risk Adjustment Data Validation (RADV) auditor and educator, and most recently, she led the risk adjustment department at a large payviders health plan. Her impressive career spans third-party billing management, leading accounts receivable in provider offices, achieving remarkably low error rates in both ACA and CMS RADV audits, and maintaining strong compliance standards across healthcare operations. Most recently, Wynda has been serving as a consultant to the company and is truly inspired by her engagement. In her new role, she will bring her years of experience in risk adjustment coding, as well as working with RAAPID’s Product & Go to Market teams to provide input, guidance, user and leadership expertise on the current and future industry challenges and Raapid’s initiatives to change the way Risk Adjustment is delivered positively. As an industry veteran who frequently delivers thought leadership at conferences and events, RAAPID welcomes Wyanda’s forthcoming contributions.

Haynes brings over 25 years of experience in program management, partner success, and strategic business development, with significant experience at Microsoft for startups as a Senior Consultant and Partner Development Manager. He specializes in driving Independent Software Vendor (ISV) startup success, implementing co-sell strategies, creating go-to-market plans, and building strong partner relationships. His extensive background in cloud solutions, Software as a Service (SaaS) marketing, and cross-functional collaboration will be instrumental in RAAPID’s continued growth.

“We’re excited to welcome Wynda and Derek,” said Chetan Parikh, Founder & CEO at RAAPID. “Their proven expertise is precisely aligned with our strategic goals, significantly accelerating our ability to deliver cutting-edge risk adjustment solutions to our customers at scale.”

These strategic hires come when RAAPID expands its presence in the value-based care technology market. The company’s purpose-built AI-powered risk adjustment solutions help payers, pay-viders, and healthcare organizations who are risk-bearing improve accuracy and efficiency in risk adjustment coding, capturing appropriate revenue while ensuring regulatory compliance.

RAAPID’s platform uses purpose-built AI, specifically the evolving neuro-symbolic approach to AI technology, to analyze clinical documentation, identify care gaps, and capture accurate risk scores from unstructured & structured healthcare data. The company serves both payers and providers with its prospective and retrospective risk adjustment solutions, helping healthcare organizations optimize reimbursement while improving patient care.

About RAAPID 
RAAPID develops AI-powered risk adjustment solutions for healthcare payers, providers, and supporting organizations. The company’s cloud-based risk adjustment platform uses neuro-symbolic AI to identify chronic conditions, determine HCC codes, calculate risk scores, and analyze population health trends. RAAPID serves organizations participating in Medicare Advantage, ACA, Medicare ACO, and Medicaid programs.

For more information about RAAPID’s AI-powered risk adjustment solutions, visit www.raapidinc.com.

Contact:
Mayur Vyas
Marketing Director
(502) 699-3044

View original content to download multimedia:https://www.prnewswire.com/news-releases/raapid-brings-on-healthcare-experts-to-strengthen-leadership-and-drive-growth-302411980.html

SOURCE RAAPID Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Topaz Labs announces its largest single release of AI models in company history with “Next-Gen” launch

Published

on

By

DALLAS, April 28, 2026 /PRNewswire/ — Topaz Labs, the AI image and video enhancement company, has announced four new image enhancement models and two video enhancement models across five applications. The collection of “Next-Gen” models offer powerful sharpening, denoising, and upscaling results to visual content. Image models included are Wonder 3, Denoise Max, Super Focus 3, and High Fidelity 3. For video, Starlight Precise 2.5 and Astra 2 were announced.

The collection of models offers powerful sharpening, denoising, and upscaling results to visual content.

“This is both the largest and most technically advanced set of models we’ve released in the company’s history,” says Eric Yang, CEO, Topaz Labs. “We launched Topaz NeuroStream earlier this year with the goal of enabling local rendering of complex models for more users. Without such technology, the complex, heavyweight AI models in today’s release would have been limited to cloud-only rendering, forcing users to pay per use and be reliant on internet connection. We believe local use is crucial to the future of AI in both professional and consumer use cases, and today’s release is a huge step.” 

Topaz NeuroStream is proprietary technology that reduces VRAM usage by up to 95% and allows exponentially more users on consumer-grade hardware to use AI models locally. A total of six Topaz models are now powered by NeuroStream.

Next-Gen Release Image Models 

Wonder 3: A magical, one-click sharpen, upscale, and denoise model for images.
Denoise Max: New standard for removing noise and grain in images.
Super Focus 3: Next-level sharpening model that brings subjects back from the blur.
High Fidelity 3: The newest model for upscaling high-res inputs like smartphone photos and RAW images.

All image models in this release are available in Topaz Photo desktop application and via API. Wonder 3 and Denoise Max are also available in Express, a web-based tool.

Next-Gen Release Video Models

Starlight Precise 2.5 (Local): Groundbreaking video model that brings out natural visual details with stunning results, with local availability in Topaz Video

Astra 2: The next generation of creative video upscaling that enhances clarity, richness, and visual complexity of videos by adding new detail.

Both highlighted video models are available via cloud rendering in Astra and API. Starlight Precise 2.5 (Local) can be found in the Topaz Video desktop application.

About Topaz Labs
Founded in 2005, Topaz Labs is a leader in AI-powered image and video enhancement. Its technology is used by 1.5 million customers, including 20 of the world’s top 50 companies. Known for industry-leading products like Topaz Photo, Topaz Video, Topaz Gigapixel, Astra and Bloom, the company continues to invest heavily in research and development, advancing the frontiers of imaging technology in collaboration with academic and industry partners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/topaz-labs-announces-its-largest-single-release-of-ai-models-in-company-history-with-next-gen-launch-302756375.html

SOURCE Topaz Labs

Continue Reading

Technology

Dreame Technology Launches the L60 Series, Led by the Flagship L60 Pro Ultra

Published

on

By

New lineup brings industry-leading intelligence and full-home automation to a new generation of robot vacuums

SAN FRANCISCO, April 28, 2026 /PRNewswire/ — Dreame Technology, a leader in smart home innovation, today announced the L60 Series, a new lineup of four robot vacuums engineered for the full range of modern home environments. Built on a shared foundation of premium cleaning performance, intelligent navigation, and hands-free automation, the L60 Series is designed to meet the needs of every kind of household, from compact apartments to multi-story homes, and from single-surface layouts to complex mixed-flooring environments.

“The L60 Series represents exactly what Dreame stands for: powerful, intelligent cleaning that adapts to how people actually live,” said Ana Wang, CEO of Dreame Technology North America. “Whether you have a multi-story home, pets, mixed flooring, or low furniture, there’s an L60 built for your needs. Every model in the lineup delivers the core cleaning experience our customers expect from Dreame.”

Meet the L60 Series

The L60 Series is built around four distinct models, each tailored to a different home profile and cleaning priority:

L60 Pro Ultra — The Ultimate All-in-One. The flagship vacuum is purpose-built for large floor plans, multi-surface transitions, and complex terrain. Features the 3.46-inch ProLeap™ System, 35,000Pa Vormax™ Suction, Dual Omni-Scrub Mopping with Hot Water, and an industry-leading 6,400mAh PowerCore™ Battery.L60 Ultra — Precision Whole-Home Coverage. A balanced high-performer built around Dreame’s latest 2026 sensor technology and a 3.23in (82mm) ultra-thin design for precise navigation in low-light spaces and flawless cleaning under low-profile furniture. Includes AI-Enhanced 3D ToF Vision, 35,000Pa Vormax™ Suction, HyperStream™ Detangling DuoBrush 2.0, SmartDirt™ Detection, Pet-Friendly Care 5.0, and Matter, Apple Watch, and Home Screen Shortcut support.L60 Ultra PE (Performance Edition) — The Intelligent Step-Up. An upgraded everyday performer for homes that need an extra boost on hair pickup, with 30,000Pa Vormax™ Suction, the HyperStream™ Detangling DuoBrush, 3DAdapt™ Obstacle Avoidance, and Smart Pathfinder Technology with 220 object type recognition.L60 Ultra FE (Fine Edition) — The Essential Automated Choice. An entry-level powerhouse delivering the core promise of maintenance-free floor care, with 30,000Pa Vormax™ Suction, TriCut Brush 3.0, Dual Flex Arm Technology, and the full PowerDock™ automation experience.

A Shared Foundation of Premium Performance

Every model in the L60 Series shares a core set of capabilities that set a new baseline for modern robot vacuums, including:

212°F (100°C) ThermoHub™ Mop Self-Cleaning for hygienically clean mop pads after every cycle30,000–35,000Pa Vormax™ Suction across the lineup for powerful pickup on every surfaceDual Flex Arm Technology for adaptive side-brush and mop coverage in corners and along edgesMop Lifting for seamless transitions between hard floors and carpetAutomatic Solution Dispensing for consistent cleaning chemistry without manual refillsThe 8-in-1 PowerDock™ base station, which handles auto-empty, mop washing, hot-air drying, and solution management for truly hands-free operation

L60 Pro Ultra: The Flagship Experience, Redefined for Complex Homes

Leading the lineup is the L60 Pro Ultra, featuring select top-tier specifications optimized for large-scale layouts and complex terrains. It pairs the series’ most capable hardware with Dreame’s most advanced intelligence to deliver a seamless, one-stop cleaning experience that effortlessly tackles stubborn stains across expansive and complex home layouts.

At the heart of the Pro Ultra’s navigation advantage is the 3.46-inch ProLeap™ System, the lineup’s most capable obstacle-crossing system, paired with VersaLift Navigation for cleaning under low-clearance furniture. It is equipped with dual-laser 3D structured light, an AI RGB camera, and LED illumination, enabling it to recognize over 280 types of obstacles — for precise, real-time avoidance in any lighting condition.

The Pro Ultra delivers 35,000Pa Vormax™ Suction alongside the HyperStream™ Detangling DuoBrush, together extracting embedded debris, pet hair, and fine particles from every floor type without tangles or jams. Its Dual Omni-Scrub Mopping with Hot Water system pairs rotating mop pads with a Thermal Mop Pad and ThermoHub™ 212°F (100°C) Mop Self-Cleaning, while the AceClean™ DryBoard minimizes residue — eliminating grease, bacteria, and moisture that cold-water systems simply can’t address. An industry-leading 6,400mAh PowerCore™ Battery provides whole-home coverage on a single charge.

The Pro Ultra’s OmniDirt™ Detection Technology identifies high-soil areas and automatically triggers Mop Rewashing and Floor Remopping for a truly thorough result. Pet-Friendly Care 4.0 adds pet-aware detection and navigation, while Upgraded Intelligent Carpet Cleaning optimizes suction and mop behavior for mixed-flooring homes. Direct Voice Control and app control round out the experience for effortless day-to-day use.

Pricing and Availability

The Dreame L60 Series is available now through the Dreame website and Amazon (L60 Pro Ultra, L60 Ultra, L60 Ultra PE, L60 Ultra FE), with launch-offer pricing through the official website. Customers who purchase on dreametech.com receive a free accessory kit with their order.

L60 Pro Ultra — MSRP $1,399.99 | Launch Offer $1,259.99L60 Ultra — MSRP $1,299.99 | Launch Offer $1,169.99L60 Ultra PE — MSRP $1,099.99 | Launch Offer $879.99L60 Ultra FE — MSRP $999.99 | Launch Offer $749.99

For more information about the L60 Series, visit dreametech.com/pages/l60-series-robot-vacuum.

About Dreame Technology

Established in 2017, Dreame Technology is an innovative consumer product company focused on smart home cleaning appliances with the vision to empower lives through technology. Follow us on Facebook, Instagram, TikTok and Twitter. For more information, please visit https://www.dreametech.com/.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dreame-technology-launches-the-l60-series-led-by-the-flagship-l60-pro-ultra-302756382.html

SOURCE Dreame Technology

Continue Reading

Technology

Vanda Pharmaceuticals announces the publication of “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in NEJM Evidence

Published

on

By

WASHINGTON, April 28, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled “Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis” in New England Journal of Medicine (NEJM) Evidence1.

The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration (FDA) with a target action date of December 12, 2026.

References

Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026). 

About Imsidolimab

Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s. Vanda holds an exclusive global license for the development and commercialization of imsidolimab from AnaptysBio (Nasdaq: ANAB).

About Vanda Pharmaceuticals

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including, but not limited to statements regarding the anticipated timing of the completion of the FDA’s review of the imsidolimab BLA; Vanda’s plans to seek FDA approval of imsidolimab for the treatment of GPP; and the potential to extend regulatory and patent exclusivity for imsidolimab into the late 2030s, are “forward-looking statements” under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, the FDA’s ability to complete its review of, and reach a decision with respect to, the imsidolimab BLA by December 12, 2026; Vanda’s ability to obtain FDA approval of imsidolimab for the treatment of GPP; and Vanda’s ability to satisfy the conditions necessary to extend regulatory and patent exclusivity for imsidolimab into the late 2030s. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized, or even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the “Cautionary Note Regarding Forward-Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s most recent Annual Report on Form 10-K, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-imsidolimab-for-generalized-pustular-psoriasis-in-nejm-evidence-302756392.html

SOURCE Vanda Pharmaceuticals Inc.

Continue Reading

Trending